The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma

Objective: Chordoma is a rare malignant bone tumor with a poor outcome. Although radiotherapy and gamma knife surgery have been used for treatment, providing a cure for the tumor is not easy, because of the frequent recurrences. Molecular targeted therapy against tyrosine kinases has been effective...

Full description

Bibliographic Details
Main Authors: Zeynep TOSUNER, Türker KILIÇ, Baran YILMAZ
Format: Article
Language:English
Published: Federation of Turkish Pathology Societies 2017-05-01
Series:Türk Patoloji Dergisi
Subjects:
Online Access:http://www.turkjpath.org/pdf.php3?id=1815
id doaj-e010e7e1544b4b3881487c0079a52533
record_format Article
spelling doaj-e010e7e1544b4b3881487c0079a525332020-11-24T23:22:57ZengFederation of Turkish Pathology SocietiesTürk Patoloji Dergisi1018-56151309-57302017-05-0133211212010.5146/tjpath.2016.01378 The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma Zeynep TOSUNERZeynep TOSUNERTürker KILIÇBaran YILMAZObjective: Chordoma is a rare malignant bone tumor with a poor outcome. Although radiotherapy and gamma knife surgery have been used for treatment, providing a cure for the tumor is not easy, because of the frequent recurrences. Molecular targeted therapy against tyrosine kinases has been effective in the treatment of malignancies such as breast and lung cancers and brain tumors. We aimed to analyse the histopathological features of chordomas and the immunoexpression profiles of the three receptor tyrosine kinases of EGFR, c-Met and c-Erb-B2 in chordomas. We have correlated these results with recurrence and overall survival status of the patients. Material and Method: We studied 49 chordoma patients in order to evaluate the histopathological features and immunohistochemical stainings by EGFR, c-Met and c-ErbB2 antibodies. Of the 49 patients, follow up data was available for 40 patients. Clinical data of the patients were correlated with histopathological features and survival analysis was performed. Results: The immunostaining rate by EGFR and c-Met was 73.5% and 12.2% respectively. None of the cases showed immunoreactivity by c-ErbB2 (0%). Of the 40 cases, 17 cases showed recurrences. EGFR expression was detected in 14 recurrent (14/17) and 17 non-recurrent cases (17/23). Four of the 17 recurrent cases (4/17) were positive by c-Met, while none of the non-recurrent cases (0/23) were positive by this antibody. Significantly, all cases with positive c-Met expression showed recurrences (p<0.05). Conclusion: Our study indicates that EGFR expression is detected in the majority of chordoma cases. c-Met expression can be used as a prognostic indicator for chordoma.http://www.turkjpath.org/pdf.php3?id=1815ChordomaEGFRc-Metc-Erb B2
collection DOAJ
language English
format Article
sources DOAJ
author Zeynep TOSUNER
Zeynep TOSUNER
Türker KILIÇ
Baran YILMAZ
spellingShingle Zeynep TOSUNER
Zeynep TOSUNER
Türker KILIÇ
Baran YILMAZ
The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
Türk Patoloji Dergisi
Chordoma
EGFR
c-Met
c-Erb B2
author_facet Zeynep TOSUNER
Zeynep TOSUNER
Türker KILIÇ
Baran YILMAZ
author_sort Zeynep TOSUNER
title The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
title_short The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
title_full The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
title_fullStr The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
title_full_unstemmed The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma
title_sort role of egfr, hepatocyte growth factor receptor (c-met), c-erbb2 (her2-neu) and clinicopathological parameters in the pathogenesis and prognosis of chordoma
publisher Federation of Turkish Pathology Societies
series Türk Patoloji Dergisi
issn 1018-5615
1309-5730
publishDate 2017-05-01
description Objective: Chordoma is a rare malignant bone tumor with a poor outcome. Although radiotherapy and gamma knife surgery have been used for treatment, providing a cure for the tumor is not easy, because of the frequent recurrences. Molecular targeted therapy against tyrosine kinases has been effective in the treatment of malignancies such as breast and lung cancers and brain tumors. We aimed to analyse the histopathological features of chordomas and the immunoexpression profiles of the three receptor tyrosine kinases of EGFR, c-Met and c-Erb-B2 in chordomas. We have correlated these results with recurrence and overall survival status of the patients. Material and Method: We studied 49 chordoma patients in order to evaluate the histopathological features and immunohistochemical stainings by EGFR, c-Met and c-ErbB2 antibodies. Of the 49 patients, follow up data was available for 40 patients. Clinical data of the patients were correlated with histopathological features and survival analysis was performed. Results: The immunostaining rate by EGFR and c-Met was 73.5% and 12.2% respectively. None of the cases showed immunoreactivity by c-ErbB2 (0%). Of the 40 cases, 17 cases showed recurrences. EGFR expression was detected in 14 recurrent (14/17) and 17 non-recurrent cases (17/23). Four of the 17 recurrent cases (4/17) were positive by c-Met, while none of the non-recurrent cases (0/23) were positive by this antibody. Significantly, all cases with positive c-Met expression showed recurrences (p<0.05). Conclusion: Our study indicates that EGFR expression is detected in the majority of chordoma cases. c-Met expression can be used as a prognostic indicator for chordoma.
topic Chordoma
EGFR
c-Met
c-Erb B2
url http://www.turkjpath.org/pdf.php3?id=1815
work_keys_str_mv AT zeyneptosuner theroleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT zeyneptosuner theroleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT turkerkilic theroleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT baranyilmaz theroleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT zeyneptosuner roleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT zeyneptosuner roleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT turkerkilic roleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
AT baranyilmaz roleofegfrhepatocytegrowthfactorreceptorcmetcerbb2her2neuandclinicopathologicalparametersinthepathogenesisandprognosisofchordoma
_version_ 1725566134782001152